Esophageal cancer is one of the most malignant digestive system tumors and the seventh most common cancer worldwide. The latest global cancer statistics show that there are approximately 604,100 new cases of esophageal cancer and 544,076 deaths worldwide each year. Despite recent advances in surgery, radiotherapy, chemotherapy and immunotherapy, the 5-year survival rate for patients with esophageal cancer remains low. Its diagnosis and prognosis face the following three challenges: late presentation of symptoms, cost or discomfort of endoscopy, and insensitivity and non-specificity of biomarkers.
With the completion of the Human Genome Project and the development of other model organism genome programs, high-throughput sequencing technologies have availed us of massive amounts of sequencing data, including genomes, epigenomes, transcriptomes, proteomes, and metabolomes. This data creates avenues for comprehensive cancer analysis that can help us explain the complexity of biomolecules and their mechanisms of action at multiple levels.
The goal of this Research Topic is to provide an overview of the status and recent findings from multi-omics esophageal cancer including predictors of tumorigenesis, progression, and immune escape, and to provide new directions for early diagnosis, characterization, and prognostic guidance of esophageal cancer in the clinic.
We welcome submissions of various types of manuscripts, including original papers, reviews, and methods, including but not limited to:
• Genetic signatures for early diagnosis and prognostic prediction of esophageal cancer.
• Multi-omics analyses, including genomics, transcriptomics, single cell genomics, or proteomics, for the molecular mechanisms of tumor cell occurrence, development, drug/radiation resistance, and immune escape in esophageal cancer.
• Identification of precise genetic targets for future therapy, immunotherapy, and radiotherapy.
Please note:
• Manuscripts based on re-analysis of pre-existing data collections will only be considered when including appropriate experimental validation or in the context of novel data analysis methodologies and verification through independent datasets.
• Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Genetics.
Esophageal cancer is one of the most malignant digestive system tumors and the seventh most common cancer worldwide. The latest global cancer statistics show that there are approximately 604,100 new cases of esophageal cancer and 544,076 deaths worldwide each year. Despite recent advances in surgery, radiotherapy, chemotherapy and immunotherapy, the 5-year survival rate for patients with esophageal cancer remains low. Its diagnosis and prognosis face the following three challenges: late presentation of symptoms, cost or discomfort of endoscopy, and insensitivity and non-specificity of biomarkers.
With the completion of the Human Genome Project and the development of other model organism genome programs, high-throughput sequencing technologies have availed us of massive amounts of sequencing data, including genomes, epigenomes, transcriptomes, proteomes, and metabolomes. This data creates avenues for comprehensive cancer analysis that can help us explain the complexity of biomolecules and their mechanisms of action at multiple levels.
The goal of this Research Topic is to provide an overview of the status and recent findings from multi-omics esophageal cancer including predictors of tumorigenesis, progression, and immune escape, and to provide new directions for early diagnosis, characterization, and prognostic guidance of esophageal cancer in the clinic.
We welcome submissions of various types of manuscripts, including original papers, reviews, and methods, including but not limited to:
• Genetic signatures for early diagnosis and prognostic prediction of esophageal cancer.
• Multi-omics analyses, including genomics, transcriptomics, single cell genomics, or proteomics, for the molecular mechanisms of tumor cell occurrence, development, drug/radiation resistance, and immune escape in esophageal cancer.
• Identification of precise genetic targets for future therapy, immunotherapy, and radiotherapy.
Please note:
• Manuscripts based on re-analysis of pre-existing data collections will only be considered when including appropriate experimental validation or in the context of novel data analysis methodologies and verification through independent datasets.
• Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in Frontiers in Genetics.